ClinicalTrials.gg
CompletedNCT00380939Updated Dec 4, 2006

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

A Phase 4 interventional study of Atorvastatin and Pravastatin in Coronary Arteriosclerosis, sponsored by Pfizer. Completed at 36 sites in United States. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2006-12-04.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.

Enrollment
3rd of 33
600 · median 120
Started
1999
the only one that year
Phase 4
19 of 33
1 open now
Registered
4th of 33
by date
Lead sponsor
2 of 33
Pfizer

Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one is the 3rd largest by enrollment, is the only one that started in 1999, is one of 19 in phase 4, and was the 4th registered.

Coronary Artery Disease

4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing atorvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.

03

Conditions studied

  • Coronary Arteriosclerosis
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Angiographic evidence of coronary artery disease as defined by a lesion that has at least 20% reduction in luman diameter by visual (angiographic) estimation in any native coronary artery. LDL cholesterol equal to 125mg/dl - 210mg/dl.

Exclusion criteria

Exclusion Criteria:

  • Patients who are anticipated to undergo coronary bypass surgery or cardiac transplantation during the course of the study. Known major hematologic, neoplastic, metabolic, gastrointestinal or endocrine dysfunction.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
600 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary efficacy parameter is the percent change in total plaque volume for all slices of anatomically comparable segments of the target coronary artery from baseline to month 18.

  2. The primary efficacy parameter for brachial artery vasoactivity is the nominal change (month 3 - baseline) in the percent arterial diameter change.

Secondary outcomes

  1. The nominal change (month 18 - baseline) in total plaque volume as measured by the sum of plaque areas for all slices of anatomically comparable segments of the target coronary artery.

  2. Changes in brachial artery vasoactivity will be correlated with changes in total cholesterol, LDL-C, triglyceride and apolipoprotein B levels following 3 months of treatment.

07

Study locations

36 sites
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Los Angeles, California 90048, United States
  • Pfizer Investigational Site
    Los Angeles, California 90095, United States
  • Pfizer Investigational Site
    San Diego, California 92103-8411, United States
  • Pfizer Investigational Site
    Denver, Colorado 80262, United States
  • Pfizer Investigational Site
    Blue Island, Florida 60406, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32610, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30309, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Shawnee Mission, Kansas 66204, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40202, United States
  • Pfizer Investigational Site
    Auburn, Maine 04210, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02111, United States
  • Pfizer Investigational Site
    Kalamazoo, Michigan 49001, United States
  • Pfizer Investigational Site
    Royal Oak, Michigan 48073, United States
  • Pfizer Investigational Site
    St Clair, Michigan 48080, United States
  • Pfizer Investigational Site
    Rochester, Minnesota 55905, United States
  • Pfizer Investigational Site
    Albany, New York 12208, United States
  • Pfizer Investigational Site
    New York, New York 10029, United States
  • Pfizer Investigational Site
    Williamsville, New York 14221, United States
  • Pfizer Investigational Site
    Chapel Hill, North Carolina 27599-7594, United States
  • Pfizer Investigational Site
    Greensboro, North Carolina 27403, United States
  • Pfizer Investigational Site
    Greenville, North Carolina 27858-4354, United States
  • Pfizer Investigational Site
    Winston Salem, North Carolina 27157, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44106, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195-5066, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Pfizer Investigational Site
    Elryia, Ohio 44035, United States
  • Pfizer Investigational Site
    Toledo, Ohio 43614, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma, United States
  • Pfizer Investigational Site
    Allentown, Pennsylvania 18106, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02903, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02906, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78284-6205, United States
  • Pfizer Investigational Site
    Seattle, Washington 98195, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1999 and a completion of Dec 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2006
First posted
Sep 27, 2006
Start
Apr 1999
Completion
Dec 2000
Last update
Dec 4, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Dec 4, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00380939
Lead sponsor
Pfizer
First posted
Sep 27, 2006
Start date
Apr 1999
Completion
Dec 2000
Last update
Dec 4, 2006

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atorvastatin · Pravastatin

Start the discussion